

# TEST SUMMARY

## Anti-CFH Antibody

Chromogenic ELISA for the quantitative detection of anti-complement factor H (CFH) antibodies. Factor H is a regulator of the alternative complement activation pathway. Acquired Factor H deficiency due to autoantibody production can lead to overactive complement. Continuous complement activation is associated with development of atypical Hemolytic Uremic Syndrome (aHUS) and Dense Deposit Disease (DDD).

Please visit [Machaondiagnosics.com](http://Machaondiagnosics.com) for further information.

*Limitations: Anti-CFH autoantibody levels may be significantly reduced by treatments such as plasmapheresis, rituximab, or cyclophosphamide therapy (Khandelwal (2015) *Pediatr Nephrol* 30, 3).*

*References: 1. Dragon-Durey M, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2005;16:555-563. 2. Dragon-Durey M, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. *J Am Soc Nephrol* 2010;21:2180-2187.*



**DRAW KITS AVAILABLE**

### WHY CHOOSE US?

- ✓ Fast turnaround times
- ✓ Draw kits (includes free shipping)
- ✓ Clinical consultation
- ✓ Critical Results called to physician

### SPECIMEN REQUIREMENTS

1mL Serum

### STABILITY

Room Temp.: 7 days  
Refrigerated: 7 days  
Frozen (-20C): 2 weeks  
Frozen (-80C): 6 months

### CPT CODE

83516

### METHODOLOGY

ELISA

### TURNAROUND TIMES

Routine TAT: <5 days (M-F)  
STAT TAT: <48 hours (M-F)

### ALTERNATIVE NAMES

Anti-Complement Factor H Antibody  
Complement Factor H Autoantibody

### NEW YORK STATE APPROVED

YES

### ABOUT US:

Machaon Diagnostics is a clinical reference laboratory, specializing in coagulation, platelets, complement, genetics and rare disease.

